Featured Post from Aston University

Aston University researchers collaborate with biotechnology start-up to develop drugs to tackle irreversible lung disease

Jan 23, 2023

3 min



• Researchers in the School of Biosciences partner with preclinical-stage biotechnology start-up company to develop drugs for fibrotic diseases

• Professor Martin Griffin and team develop TG2 inhibitors to help treat a serious chronic lung disease called idiopathic pulmonary fibrosis.

• Isterian Biotech is part of Cambrian BioPharma who have been working with Aston University since 2019.


Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease.


The focus of preclinical-stage biotechnology company Isterian Biotech is on developing novel drugs to stop or reverse the pathological accumulation of crosslinked proteins commonly observed in all major organs with age.


As we age a chronic increase of crosslinked proteins occurs in the extracellular matrix (ECM), that surround, support, and give structure to the cells and tissues in the body. These crosslinked proteins are difficult for the body to degrade and over time can make organs stiff and dysfunctional, ultimately resulting in fibrosis. Reversing the accumulation of these pathological crosslinks will greatly contribute to reducing fibrosis.


The start-up is working to develop small molecule inhibitors of transglutaminase 2 also known as TG2, which is one of the major crosslinking enzymes in the human body, that becomes more active during ageing - thus resulting in fibrotic diseases such as a type of lung disease known as idiopathic pulmonary fibrosis (IPF).


Isterian President and Chairman of the Board, Georg C Terstappen, PhD said:


"Isterian's strategy of combining rational drug design with efficient multiparametric profiling of synthesized small molecules has been both impressive and highly productive. Notably, for one of our highly potent and selective TG2 inhibitors, we have recently demonstrated efficacy in a mouse model of lung fibrosis for the first time.

"Using this state-of-the-art approach to drug discovery combined with an impressive team gives us great confidence in the future of this novel company."


IPF is a progressive, irreversible disease that is characterized by pathological crosslinking of extracellular matrix (ECM) proteins (a large network of proteins and other molecules that surround, support, and give structure to the cells and tissues in the body) leading to excessive deposition of collagen. This means that in IPF scar tissue or fibrosis builds up around the air sacs (alveoli) in the lungs and reduces the ability to transfer oxygen that is breathed into the blood, resulting in severe restriction of lung capacity and function.


IPF is the most common form of pulmonary fibrosis. The disease affects between 200,000 and 300,000 people globally. Statistics from the charity Action for Pulmonary Fibrosis suggest there are about 30,000 people living with IPF in the UK with an estimated 6,000 new cases of the condition each year. The disease usually develops in people aged 70 and older and is more common in men. But it can occur in younger individuals, particularly if there is a family history of idiopathic pulmonary fibrosis.


The company was founded by capitalizing on over 35 years of scientific research from the laboratory of Professor Martin Griffin and his team Dr Dan Rathbone and Dr Vivian Wang at Aston University.


Their work with small molecule inhibitors selective for TG2 has demonstrated reduction of fibrosis in multiple organs in a number of animal models. In 2019, Aston University partnered with Cambrian to form Isterian Biotech with a mission to develop safe and effective TG2 inhibitors to treat Idiopathic pulmonary fibrosis (IPF), a devastating fibrotic disease of the lung.


Professor Martin Griffin, Biosciences Research Group, Aston University said: “We are delighted to continue our work with Isterian researching how we can further develop TG2 inhibitors to help tackle this awful disease.”


CEO of Cambrian BioPharma, James Peyer, commented: "As Cambrian continues on its mission to build medicines that will redefine healthcare in the 21st century, we are very thankful to find brilliant scientists such as Martin and his team that are willing to break the mold. Isterian and its work to reduce fibrosis are a perfect fit alongside the other pipeline companies our team has announced in 2022."


The company's current pipeline includes an advanced preclinical-stage TG2 inhibitor for inhaled administration and several structurally unrelated back-up compounds for the treatment of IPF.


For more information about the School of Biosciences at Aston University, please visit our website.



You might also like...

Check out some other posts from Aston University

2 min

Aston University researcher takes on leadership role within biomedical engineering

Dr Antonio Fratini is the new chair of the Institute of Mechanical Engineers Biomedical Engineering Division It is one of the largest group of professional biomedical engineers in the UK The specialism merges professional engineering with medical knowledge of the human body, such as artificial limbs and robotic surgery. An Aston University researcher has been given a leading role within the biomedical engineering sector. Dr Antonio Fratini CEng MIMechE has been elected as the new chair of the Biomedical Engineering Division (BmED) of the Institution of Mechanical Engineers (IMechE), one of the largest groups of professional biomedical engineers in the UK. The IMechE has around 115,000 members in 140 countries and has been active since 1847. Biomedical engineering, also known as medical engineering or bioengineering, is the integration of engineering with medical knowledge to help tackle clinical problems and improve healthcare outcomes. Dr Fratini previously served as chair of the Birmingham centre of the division for five years and as vice-chair of the division for one year. His research includes responsible use of AI, 3D segmentation and anatomical modelling to improve surgical training and planning, motor functions and balance rehabilitation. He leads Aston University’s Engineering for Health Research Centre within the College of Engineering and Physical Sciences and has vast experience in the design, development and testing of new medical devices. Currently he is the University’s principal investigator for the West Midlands Health Tech Innovation Accelerator and he has a growing reputation in the UK and internationally within the biomedical engineering profession. He said: “Biomedical engineering is continuously evolving and our graduates will create the future of health tech and med tech for more effective, sustainable, responsible and personalised healthcare. “I am very honoured of this appointment. This three-year post will be a great opportunity to further develop the biomedical engineering profession worldwide and to show Aston University’s commitment to an inclusive, entrepreneurial and transformational impact within the field.” Professor Helen Meese, outgoing chair of the division, said: “I am delighted to see Antonio take on the chair’s position. He has, over the years, contributed significantly to the growth of the Birmingham regional centre and has actively supported me throughout my tenure as chair. I know how passionate he is about our profession and will undoubtedly continue to drive the division forward over the next three years.” Dr Frattini was presented with his new title on 20 June at the IMECHE HQ at 1 Birdcage Walk, London during the Institution’s technology strategy board meeting. For media inquiries in relation to this release, contact Nicola Jones, Press and Communications Manager, on (+44) 7825 342091 or email: n.jones6@aston.ac.uk

3 min

Aston University researcher develops method of making lengthy privacy notices easier to understand

It has been estimated it would take 76 days per year to fully read privacy notices New method makes notices quicker and easier to understand by converting them into machine-readable formats Team designed a JavaScript Object Notation schema which allowed them to validate, annotate, and manipulate documents. An Aston University researcher has suggested a more human-friendly way of reading websites’ long-winded privacy notices. A team led by Dr Vitor Jesus has developed a system of making them quicker and easier to understand by converting them into machine-readable formats. This technique could allow the browser to guide the user through the document with recommendations or highlights of key points. Providing privacy information is one of the key requirements of the UK General Data Protection Regulation (GDPR) and the UK Data protection Act but trawling through them can be a tedious manual process. In 2012, The Atlantic magazine estimated it would take 76 days per year to diligently read privacy notices. Privacy notices let people know what is being done with their data, how it will be kept safe if it’s shared with anyone else and what will happen to it when it’s no longer needed. However, the documents are written in non-computer, often legal language, so in the paper Feasibility of Structured, Machine-Readable Privacy Notices Dr Jesus and his team explored the feasibility of representing privacy notices in a machine-readable format. Dr Jesus said: “The notices are essential to keep the public informed and data controllers accountable, however they inherit a pragmatism that was designed for different contexts such as software licences or to meet the - perhaps not always necessary - verbose completeness of a legal contract. “And there are further challenges concerning updates to notices, another requirement by law, and these are often communicated off-band e.g., by email if a user account exists.” Between August and September 2022, the team examined the privacy notices of 50 of the UK’s most popular websites, from globally organisation such as google.com to UK sites such as john-lewis.com. They covered a number of areas such as online services, news and fashion to be representative. The researchers manually identified the notices’ apparent structure and noted commonly-themed sections, then designed a JavaScript Object Notation (JSON) schema which allowed them to validate, annotate, and manipulate documents. After identifying an overall potential structure, they revisited each notice to convert them into a format that was machine readable but didn’t compromise both legal compliance and the rights of individuals. Although there has been previous work to tackle the same problem, the Aston University team focused primarily on automating the policies rather than data collection and processing. Dr Jesus, who is based at the University’s College of Engineering and Physical Sciences said: “Our research paper offers a novel approach to the long-standing problem of the interface of humans and online privacy notices. “As literature and practice, and even art, for more than a decade have identified, privacy notices are nearly always ignored and ”accepted” with little thought, mostly because it is not practical nor user-friendly to depend on reading a long text simply to access, for example a news website. Nevertheless, privacy notices are a central element in our digital lives, often mandated by law, and with dire, often invisible, consequences.” The paper was published and won best paper at the International Conference on Behavioural and Social Computing, November 2023, now indexed at IEEE Xplore. The team are now examining if AI can be used to further speed up the process by providing recommendations to the user, based on past preferences.

2 min

Aston University optometrists take up global industry association roles

Professor Nicola Logan has been named a global myopia management ambassador by the World Council of Optometry Dr Debarun Dutta is the new academic chair of the British Contact Lens Association Aston University School of Optometry is ranked in the top 10 for research in the Complete University Guide 2024 Professor Nicola Logan and Dr Debarun Dutta from Aston University’s School of Optometry have both been appointed to major roles within optometry industry associations. The School of Optometry is regularly ranked highly by both leading national ranking publications and in annual student-led surveys. This includes a top 10 ranking for research and a top five ranking for graduate prospects in the Complete University Guide 2024, and first in the UK for student/staff ratio in health professions (optometry) in the Guardian University Guide 2024. Professor Logan, professor of optometry and physiological optics and deputy head of the School, has been named a global myopia management ambassador by the World Council of Optometry (WCO). She is one of four new ambassadors named by the WCO in collaboration with CooperVision, a leading myopia management company. WCO and CooperVision have developed a myopia management online tool which reflects WCO’s global standard of myopia care. In March 2024, Professor Logan presented her inaugural lecture at Aston University on her research into the nature of myopia, the growing evidence base on strategies to control eye growth in children and translation of these findings to clinical practice. She said about her appointment as an ambassador: “I am thrilled to be appointed as the global myopia management ambassador for the World Council of Optometry. This role provides me with a valuable platform to advance the recognition of myopia as a significant public health concern and to facilitate the translation of research into effective, evidence-based clinical practice strategies for children with myopia.” Dr Dutta, a lecturer in optometry, has been appointed the new academic chair of the British Contact Lens Association (BCLA). He will lead the BCLA’s academic output, including offering guidance and advice to the BCLA council about scientific and academic elements of contact lenses. Dr Dutta will initially work alongside current academic chair, Professor James Wolffsohn, Aston University’s head of optometry, who is currently on sabbatical from the University, before taking over when Professor Wolffsohn steps down in 2025. Dr Dutta said: “I am hugely excited at the prospect of delivering academic provision of the British Contact Lens Association, with a specific focus on a highly prestigious conference programme as we grow our reputation as a global leader in contact lens and anterior eye education. This is a rare opportunity to work alongside our association members, fellows, trustees, global ambassadors and volunteers inspiring a new era for the BCLA, and to support our growth and development ambitions through delivery of educational activities within the contact lens and anterior eye specialism.”

View all posts
Powered by